Development of a bivalent vaccine against Acinetobacter baumannii (A. baumannii) and Streptococcus agalactiae (S. agalactiae)

Ellen Jessouroun

Dr Ellen Jessouroun
Bacterial Development Program Manager
Technological development department
Bio-Manguinhos, Oswaldo Cruz Foundation-Fiocruz  (Brazil)


Dr José Procópio Moreno Senna, Technological Development Department Bio-Manguinhos, Oswaldo Cruz Foundation-Fiocruz (Brazil)
Dr Barbara Bolgiano, Division of Bacteriology, National Institute for Biological Standards and Control (UK)
Dr Nicola Beresford, Division of Bacteriology, National Institute for Biological Standards and Control (UK)


Antimicrobial costs have been increasing steadily every year and special attention has been given by Brazilian public agencies, such as the National Agency of Sanitary Surveillance (ANVISA), to resistant bacterial infections. The study proposal is the development of a bivalent conjugate vaccine against A. baumannii and S. agalactiae which cause a high incidence of infections in hospitals in Brazil. The Streptococcus species also causes meningitis in newborn babies. This vaccine project targets two groups: adults susceptible to hospital-acquired infections, and pregnant women, who are at risk of S. agalactiae infection.  Taking advantage of the skills acquired by Bio-Manguinhos, from Oswaldo Cruz Foundation, in the development of conjugate vaccines for meningococcus, the study intends to develop a vaccine obtained by the chemical conjugation between the capsular polysaccharide of S. agalactiae and the major outer membrane (OM) protein, OmpA, from outer membrane vesicles (OMVs) from A. baumannii. The effectiveness of the vaccine, in inducing protection against the two target bacteria, will be assessed in mice. The proposal goal will be the search of correlates of immunity, through the evaluation of the induced antibody functionality and the changes to adhesion pattern of the two microorganisms to epithelial cell monolayers. Bio-Manguinhos will produce the experimental vaccines, immunize the mice and evaluate the functionality of the induced antibodies to protect against the two vaccine target pathogens. The adhesion test will be also performed by Bio-Manguinhos. NIBSC, the National Control Laboratory of the U.K. will evaluate the quality of glycoconjugate and OMV vaccines and components.